Johnson & Johnson has been fined more than $2.2bn by US federal and State authorities for kickbacks and promotional activities of its medicines for diseases beyond their approved uses over more than a decade. In the largest of a series of settlements involving the US healthcare group, J&J pleaded guilty to a misdemeanor linked to its past selling practices for Risperdal, its anti-psychotic drug and its marketing of the drugs Invega for schizophrenia, and Natricore for heart failure.
